# QUANTUM PHASE 5.5.0.5: HUMAN DECISION WORKSHEET

**Worksheet Status:** `UNEXECUTED_WORKSHEET_AWAITING_HUMAN_SIGN_OFF`  
**Publication Timestamp:** `2026-11-01 21:02:03 UTC`  
**Repository:** `https://github.com/RAYDENFLY/quantum-multi-agent`  

---

## INSTRUCTIONS FOR HUMAN SUPERVISOR

Review the challenged definitions in `docs/research/phase_5_5_0_5/`. For each decision below, complete the fields. All fields remain pending until signed by the supervisor.

---

## DECISION 1: BARRIER EXECUTION ARCHITECTURE (DEC_01)
- **Question:** Does Phase 5.5 validate the raw frozen ML classifier (Alternative B) or explore an independent downstream trading strategy (Alternative C)?
- **Options:** `Alternative B` (Re-Anchor Symmetric) / `Alternative C` (Independent Policy) / `Sequential Track` (B then C)
- **Consequences:** Alt B cleanly confirms/refutes ML model alpha. Alt C introduces exit parameters requiring walk-forward tuning on Folds 1-4.
- **Evidence Limitations:** Canonical Parquet lacks tick depth; opening gaps cause divergence between $\text{close}[i]$ and $\text{open}[i+1]$.
- **Recommended Choice:** `Alternative B` for Phase 5.5, with `Alternative C` reserved for exploratory Phase 5.5.2.
- **Human Selection:** `[PENDING_HUMAN_SELECTION]`
- **Human Rationale:** `[PENDING_HUMAN_INPUT]`
- **Approval Timestamp:** `[PENDING_HUMAN_TIMESTAMP]`
- **Status:** `PENDING_HUMAN_DECISION`

---

## DECISION 2: DIRECTIONAL TRADING SCOPE (DEC_02)
- **Question:** Should the strategy execute Long-only, Short-only, or Bidirectional positions?
- **Options:** `Long-only` / `Short-only` / `Bidirectional with mandatory separate reporting`
- **Consequences:** Bidirectional doubles signal opportunity but risks hiding Short losses behind bull market Long gains.
- **Evidence Limitations:** Funding rate is unverified in dataset; short liquidation slippage is a theoretical stylized fact.
- **Recommended Choice:** `Bidirectional with mandatory separate reporting`.
- **Human Selection:** `[PENDING_HUMAN_SELECTION]`
- **Human Rationale:** `[PENDING_HUMAN_INPUT]`
- **Approval Timestamp:** `[PENDING_HUMAN_TIMESTAMP]`
- **Status:** `PENDING_HUMAN_DECISION`

---

## DECISION 3: FUNDING RATE MODEL APPROVAL (DEC_03)
- **Question:** How should unobserved funding cash flows be modeled in Phase 5.5?
- **Options:** `Parametric sweep [-1.0, 0.0, +1.0, +3.0 bps/settle]` / `Require external backfill`
- **Consequences:** Parametric sweep enables research without delay but cannot prove historical realized net PnL.
- **Evidence Limitations:** Canonical Parquet has no funding records (`FUNDING_DATA_UNAVAILABLE`).
- **Recommended Choice:** `Parametric sweep approved as unverified assumption`.
- **Human Selection:** `[PENDING_HUMAN_SELECTION]`
- **Human Rationale:** `[PENDING_HUMAN_INPUT]`
- **Approval Timestamp:** `[PENDING_HUMAN_TIMESTAMP]`
- **Status:** `PENDING_HUMAN_DECISION`

---

## DECISION 4: PRIMARY COST GATE TIER (DEC_04)
- **Question:** What round-trip friction hurdle constitutes the mandatory break-even filter for Gate 2?
- **Options:** `15 bps (Base)` / `20 bps (Conservative Gate)` / `30 bps (Severe Stress)`
- **Consequences:** 15 bps risks false-positive alpha; 30 bps risks prematurely killing viable models.
- **Evidence Limitations:** Modeled taker fees (10 bps) + slippage (7.83 bps) yield 17.83 bps friction, but lack exchange execution logs.
- **Recommended Choice:** `20 bps Conservative Tier`.
- **Human Selection:** `[PENDING_HUMAN_SELECTION]`
- **Human Rationale:** `[PENDING_HUMAN_INPUT]`
- **Approval Timestamp:** `[PENDING_HUMAN_TIMESTAMP]`
- **Status:** `PENDING_HUMAN_DECISION`

---

## DECISION 5: PORTFOLIO CONCURRENCY AND LEVERAGE (DEC_05)
- **Question:** What are the maximum concurrent positions and gross leverage limits?
- **Options:** `Max 2 pos (2.0x)` / `Max 3 pos (3.0x)` / `Max 5 pos (5.0x)`
- **Consequences:** Higher leverage magnifies drawdowns during correlated market sell-offs.
- **Evidence Limitations:** Cross-asset correlation $\rho > 0.70$ is a domain stylized fact, unverified in repo.
- **Recommended Choice:** `Max 3 positions, max 3.0x gross leverage` with priority queue by $\Delta P$.
- **Human Selection:** `[PENDING_HUMAN_SELECTION]`
- **Human Rationale:** `[PENDING_HUMAN_INPUT]`
- **Approval Timestamp:** `[PENDING_HUMAN_TIMESTAMP]`
- **Status:** `PENDING_HUMAN_DECISION`

---

## DECISION 6: XMR RESEARCH AND PORTFOLIO SCOPE (DEC_06)
- **Question:** Should XMR be included in primary multi-asset portfolio aggregation?
- **Options:** `Exclude from primary portfolio (appendix only)` / `Include in primary portfolio`
- **Consequences:** Including XMR distorts multi-year portfolio bootstrap metrics due to 83,863 vs 316,500 candle disparity.
- **Evidence Limitations:** XMR has zero data in Folds 1-4 and only 1 minority sample in Fold 5 at 20% coverage.
- **Recommended Choice:** `Exclude from primary portfolio (report in isolated appendix)`.
- **Human Selection:** `[PENDING_HUMAN_SELECTION]`
- **Human Rationale:** `[PENDING_HUMAN_INPUT]`
- **Approval Timestamp:** `[PENDING_HUMAN_TIMESTAMP]`
- **Status:** `PENDING_HUMAN_DECISION`

---

## FORMAL EXECUTION SIGN-OFF BLOCK

- **Phase 5.5 Backtesting Authorization:** `[DENIED_UNTIL_ALL_DECISIONS_SIGNED]`
- **Supervisor Signature:** `___________________________________`
- **Date:** `[UNEXECUTED]`
